SAN
MATEO, Calif., May 16, 2024
/PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that management will
participate in a fireside chat at the A.G.P. Virtual Healthcare
conference May 21, 2024 at
10:40 a.m. ET.
Presentation Information
Presentation Date: Tuesday, May 21,
2024
Presentation Time: 10:40 am
ET
Format: Fireside Chat Webcast link: Click
here
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for use
in medically supervised settings. Talphera's lead product
candidate, Niyad™ is a lyophilized formulation of
nafamostat and is currently being studied under an investigational
device exemption, or IDE, as an anticoagulant for the
extracorporeal circuit, and has received Breakthrough Device
Designation status from the FDA. Talphera is also developing two
pre-filled syringes in-licensed from its partner Aguettant:
Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a
pre-filled phenylephrine syringe. This release is intended for
investors only. For additional information about Talphera, please
visit www.talphera.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-at-agp-virtual-healthcare-conference-302148401.html
SOURCE Talphera, Inc.